Golimumab for the treatment of Hidradenitis Suppurativa
Published: 28 May 2021| Version 1 | DOI: 10.17632/fwjvy294wy.1
Contributor:
Christopher SayedDescription
Golimumab for the Treatment of Hidradenitis Suppurativa
Files
Steps to reproduce
Subjects were identified with clinical tracking lists. Clinical data was pulled via chart review including lesion counts, demographics, disease severity, treatment duration and other clinical measures
Institutions
University of North Carolina at Chapel Hill School of Medicine
Categories
Tumor Necrosis Factor, Hidradenitis Suppurativa